{"transactions":[{"id":1475209,"issuer":{"id":74418,"kind":"organization","name":"Carisma Therapeutics Inc.","symbol":"CARM"},"owners":[{"id":89773,"kind":"person","name":"Morris Richard Steven","position":1,"cik":"0001432303","reported_name":"Morris Richard Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-18T19:08:16.000Z","date":"2024-06-17","kind":"grant","planned":false,"acquired":true,"shares":85000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest over two years, with 50% of the shares vesting on June 17, 2025 and the remaining 50% of the shares vesting on June 17, 2026, subject to continued service to Carisma Therapeutics Inc. through the applicable vesting date."}],"balance_after":85000,"derivative":{"exercise_price":1.03,"expiration_date":"2034-06-17","underlying":"Common Stock","underlying_shares":85000},"source":{"system":"sec-edgar","filing":"0001104659-24-072978","document":"tm2417501-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1485003/000110465924072978/tm2417501-3_4seq1.xml","form_type":"4"}},{"id":1661589,"issuer":{"id":74418,"kind":"organization","name":"Carisma Therapeutics Inc.","symbol":"CARM"},"owners":[{"id":89773,"kind":"person","name":"Morris Richard Steven","position":1,"cik":"0001432303","reported_name":"Morris Richard Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-02T16:53:46.000Z","date":"2024-01-31","kind":"grant","planned":false,"acquired":true,"shares":170500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest over four years in equal monthly installments, subject to continued service to Carisma Therapeutics Inc. through the applicable vesting date."}],"balance_after":170500,"derivative":{"exercise_price":2.1,"expiration_date":"2034-01-31","underlying":"Common Stock","underlying_shares":170500},"source":{"system":"sec-edgar","filing":"0001104659-24-010110","document":"tm245034-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1485003/000110465924010110/tm245034-3_4seq1.xml","form_type":"4"}},{"id":1862192,"issuer":{"id":74418,"kind":"organization","name":"Carisma Therapeutics Inc.","symbol":"CARM"},"owners":[{"id":89773,"kind":"person","name":"Morris Richard Steven","position":1,"cik":"0001432303","reported_name":"Morris Richard Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-08T18:18:16.000Z","date":"2023-06-06","kind":"grant","planned":false,"acquired":true,"shares":238000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest over four years, with 25% of the shares vesting on June 6, 2024 and the remaining shares vesting over the next three years thereafter in equal monthly installments, subject to continued service to Carisma Therapeutics Inc. through the applicable vesting date."}],"balance_after":238000,"derivative":{"exercise_price":7.25,"expiration_date":"2033-06-06","underlying":"Common Stock","underlying_shares":238000},"source":{"system":"sec-edgar","filing":"0001104659-23-069501","document":"tm2318219-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1485003/000110465923069501/tm2318219-5_4seq1.xml","form_type":"4"}},{"id":1960929,"issuer":{"id":74418,"kind":"organization","name":"Carisma Therapeutics Inc.","symbol":"CARM"},"owners":[{"id":89773,"kind":"person","name":"Morris Richard Steven","position":1,"cik":"0001432303","reported_name":"Morris Richard Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-09T21:26:15.000Z","date":"2023-03-07","kind":"grant","acquired":true,"shares":331114,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the merger of Sesen Bio, Inc. (\"Sesen Bio\") and private company CARISMA Therapeutics Inc. (\"Carisma\"), pursuant to the Agreement and Plan of Merger and Reorganization dated as of September 20, 2022, as amended by the First Amendment thereto dated as of December 29, 2022 and the Second Amendment thereto dated as of February 13, 2023 (as amended, the \"Merger Agreement\"), which closed on March 7, 2023 (the \"Closing\"), (i) each share of Carisma common stock was converted into the right to receive 1.8994 shares of Sesen Bio common stock (the \"Exchange Ratio\") and (ii) each outstanding and unexercised option to purchase shares of Carisma common stock converted into an option to purchase shares of Sesen Bio common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Exchange Ratio gives effect to the 1-for-20 reverse stock split of Sesen Bio's common stock. On the Closing date, the closing price of Sesen Bio common stock was $0.6288 (unadjusted). Upon Closing, Sesen Bio was renamed \"Carisma Therapeutics Inc.\""},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying this option vest over four years, with 25% of the shares vested on June 1, 2022 and the remaining shares vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service."}],"balance_after":331114,"derivative":{"exercise_price":1.46,"expiration_date":"2031-05-31","underlying":"Common Stock","underlying_shares":331114},"source":{"system":"sec-edgar","filing":"0001104659-23-030749","document":"tm238905-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1485003/000110465923030749/tm238905-9_4seq1.xml","form_type":"4"}},{"id":2700711,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":89773,"kind":"person","name":"Morris Richard Steven","position":1,"cik":"0001432303","reported_name":"Morris Richard Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-05-21T18:09:24.000Z","date":"2021-05-21","kind":"purchase","acquired":true,"shares":2171,"price":13.8183,"value":29999.5293,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 2020 Employee Stock Purchase Plan allocations of 1,495 shares that occurred since the date of the reporting person's last ownership report."}],"balance_after":5454,"source":{"system":"sec-edgar","filing":"0001209191-21-035059","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1432303/000120919121035059/doc4.xml","form_type":"4"}},{"id":2849831,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":89773,"kind":"person","name":"Morris Richard Steven","position":1,"cik":"0001432303","reported_name":"Morris Richard Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-18T19:33:38.000Z","date":"2021-02-16","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests as to 25% of the total shares on February 16, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":50000,"derivative":{"exercise_price":21.85,"expiration_date":"2031-02-15","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-21-012169","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1432303/000120919121012169/doc4.xml","form_type":"4"}},{"id":3231915,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":89773,"kind":"person","name":"Morris Richard Steven","position":1,"cik":"0001432303","reported_name":"Morris Richard Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-03-03T18:44:57.000Z","date":"2020-03-03","kind":"purchase","acquired":true,"shares":400,"price":18,"value":7200.0,"ownership":{"direct":true},"balance_after":400,"source":{"system":"sec-edgar","filing":"0001209191-20-015629","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1432303/000120919120015629/doc4.xml","form_type":"4"}},{"id":3237930,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":89773,"kind":"person","name":"Morris Richard Steven","position":1,"cik":"0001432303","reported_name":"Morris Richard Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-03-02T17:46:23.000Z","date":"2020-02-27","kind":"grant","acquired":true,"shares":74311,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the total shares on February 27, 2021, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on February 27, 2024, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":74311,"derivative":{"exercise_price":18,"expiration_date":"2030-02-27","underlying":"Common Stock","underlying_shares":74311},"source":{"system":"sec-edgar","filing":"0001209191-20-014685","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1432303/000120919120014685/doc4.xml","form_type":"4"}},{"id":4574945,"issuer":{"id":181526,"kind":"organization","name":"Vitae Pharmaceuticals, Inc","symbol":"VTAE"},"owners":[{"id":89773,"kind":"person","name":"Morris Richard Steven","position":1,"cik":"0001432303","reported_name":"Morris Richard Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-10-25T16:31:46.000Z","date":"2016-10-25","kind":"disposition_to_issuer","acquired":false,"shares":27500,"price":12.22,"value":336050.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option, which provided for vesting with respect to 1/4 of the shares of stock which are subject to this option on August 15, 2017 (the \"August 2017 Initial Vesting Date\") and 1/48th of the shares of stock which are subject to this option monthly following the August 2017 Initial Vesting Date, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above."}],"balance_after":0,"derivative":{"exercise_price":8.78,"expiration_date":"2026-08-14","underlying":"Common Stock","underlying_shares":27500},"source":{"system":"sec-edgar","filing":"0001104659-16-151938","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1157602/000110465916151938/a4.xml","form_type":"4"}},{"id":4574944,"issuer":{"id":181526,"kind":"organization","name":"Vitae Pharmaceuticals, Inc","symbol":"VTAE"},"owners":[{"id":89773,"kind":"person","name":"Morris Richard Steven","position":1,"cik":"0001432303","reported_name":"Morris Richard Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-10-25T16:31:46.000Z","date":"2016-10-25","kind":"disposition_to_issuer","acquired":false,"shares":27500,"price":12.42,"value":341550.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option, which provided for vesting with respect to 1/4 of the shares of stock which are subject to this option on February 15, 2017 (the \"February 2017 Initial Vesting Date\") and 1/48th of the shares of stock which are subject to this option monthly following the February 2017 Initial Vesting Date, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above."}],"balance_after":0,"derivative":{"exercise_price":8.58,"expiration_date":"2026-02-15","underlying":"Common Stock","underlying_shares":27500},"source":{"system":"sec-edgar","filing":"0001104659-16-151938","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1157602/000110465916151938/a4.xml","form_type":"4"}},{"id":4574943,"issuer":{"id":181526,"kind":"organization","name":"Vitae Pharmaceuticals, Inc","symbol":"VTAE"},"owners":[{"id":89773,"kind":"person","name":"Morris Richard Steven","position":1,"cik":"0001432303","reported_name":"Morris Richard Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-10-25T16:31:46.000Z","date":"2016-10-25","kind":"disposition_to_issuer","acquired":false,"shares":15000,"price":12.72,"value":190800.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option, which provided for vesting with respect to 1/4 of the shares of stock which are subject to this option on August 14, 2016 (the \"August 2016 Initial Vesting Date\") and 1/48th of the shares of stock which are subject to this option monthly following the August 2016 Initial Vesting Date, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above."}],"balance_after":0,"derivative":{"exercise_price":8.28,"expiration_date":"2025-08-14","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001104659-16-151938","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1157602/000110465916151938/a4.xml","form_type":"4"}},{"id":4574942,"issuer":{"id":181526,"kind":"organization","name":"Vitae Pharmaceuticals, Inc","symbol":"VTAE"},"owners":[{"id":89773,"kind":"person","name":"Morris Richard Steven","position":1,"cik":"0001432303","reported_name":"Morris Richard Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-10-25T16:31:46.000Z","date":"2016-10-25","kind":"disposition_to_issuer","acquired":false,"shares":15000,"price":6.6,"value":99000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option, which provided for vesting with respect to 1/4 of the shares of stock which are subject to this option on February 13, 2016 (the \"February 2016 Initial Vesting Date\") and 1/48th of the shares of stock which are subject to this option monthly following the February 2016 Initial Vesting Date, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above."}],"balance_after":0,"derivative":{"exercise_price":14.4,"expiration_date":"2025-02-13","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001104659-16-151938","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1157602/000110465916151938/a4.xml","form_type":"4"}},{"id":4574941,"issuer":{"id":181526,"kind":"organization","name":"Vitae Pharmaceuticals, Inc","symbol":"VTAE"},"owners":[{"id":89773,"kind":"person","name":"Morris Richard Steven","position":1,"cik":"0001432303","reported_name":"Morris Richard Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-10-25T16:31:46.000Z","date":"2016-10-25","kind":"disposition_to_issuer","acquired":false,"shares":152173,"price":15.71,"value":2390637.83,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option, which provided for vesting with respect to 1/4 of the shares of stock which are subject to this option on May 19, 2014 (the \"Initial Vesting Date\") and 1/48th of the shares of stock which are subject to this option monthly following the Initial Vesting Date, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above."}],"balance_after":0,"derivative":{"exercise_price":5.29,"expiration_date":"2024-06-24","underlying":"Common Stock","underlying_shares":152173},"source":{"system":"sec-edgar","filing":"0001104659-16-151938","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1157602/000110465916151938/a4.xml","form_type":"4"}},{"id":4574940,"issuer":{"id":181526,"kind":"organization","name":"Vitae Pharmaceuticals, Inc","symbol":"VTAE"},"owners":[{"id":89773,"kind":"person","name":"Morris Richard Steven","position":1,"cik":"0001432303","reported_name":"Morris Richard Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2016-10-25T16:31:46.000Z","date":"2016-10-25","kind":"disposition_to_issuer","acquired":false,"shares":828,"price":21,"value":17388.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc.  and Augusta Merger Sub, Inc., whereby, immediately prior to the effective time of the merger contemplated therein, all issued and outstanding shares of Issuer common stock were converted into the right to receive $21.00 per share in cash and, when so converted, automatically cancelled."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-16-151938","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157602/000110465916151938/a4.xml","form_type":"4"}}]}